^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    atirmociclib (PF-07220060)

    i
    Other names: PF-07220060, PF 07220060, PF07220060
    Company:
    Pfizer
    Drug class:
    CDK4 inhibitor
    Related drugs:
    6d
    Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=792, Recruiting, Hoffmann-La Roche | N=580 --> 792 | Trial completion date: May 2028 --> Sep 2030 | Trial primary completion date: May 2028 --> Sep 2030
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PD-L1 expression • PIK3CA mutation
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • atirmociclib (PF-07220060) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)
    6d
    A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants (clinicaltrials.gov)
    P1, N=35, Completed, Pfizer | Not yet recruiting --> Completed
    Trial completion
    |
    atirmociclib (PF-07220060)
    6d
    Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants (clinicaltrials.gov)
    P1, N=72, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    atirmociclib (PF-07220060)
    6d
    A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060 (clinicaltrials.gov)
    P1, N=28, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole • atirmociclib (PF-07220060)
    1m
    OP-1250-003: Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer (clinicaltrials.gov)
    P1, N=190, Recruiting, Olema Pharmaceuticals, Inc. | Active, not recruiting --> Recruiting | Trial completion date: Sep 2026 --> Jan 2028 | Trial primary completion date: Aug 2026 --> Dec 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    everolimus • Piqray (alpelisib) • Kisqali (ribociclib) • palazestrant (OP-1250) • atirmociclib (PF-07220060)
    2ms
    Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Pfizer
    New P1 trial
    |
    atirmociclib (PF-07220060)
    2ms
    C4391001: Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (clinicaltrials.gov)
    P2, N=362, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | Phase classification: P1 --> P2
    Enrollment closed • Phase classification
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HR positive + HER-2 positive
    |
    Xtandi (enzalutamide) • fulvestrant • letrozole • atirmociclib (PF-07220060) • midazolam hydrochloride
    2ms
    A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause (clinicaltrials.gov)
    P2, N=121, Completed, Pfizer | Recruiting --> Completed | Trial completion date: Oct 2025 --> Jul 2025 | Trial primary completion date: Oct 2025 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    letrozole • atirmociclib (PF-07220060)
    2ms
    ReDiscover: First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=930, Recruiting, Relay Therapeutics, Inc. | Trial completion date: Aug 2026 --> Apr 2027 | Trial primary completion date: Dec 2025 --> Apr 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative • PIK3CA mutation
    |
    Ibrance (palbociclib) • Kisqali (ribociclib) • fulvestrant • RLY-2608 • atirmociclib (PF-07220060)
    3ms
    PIKture-01: First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=200, Recruiting, OnKure, Inc. | N=150 --> 200
    Enrollment change
    |
    Herceptin (trastuzumab) • Kisqali (ribociclib) • fulvestrant • Tukysa (tucatinib) • OKI-219 • atirmociclib (PF-07220060)
    3ms
    A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060 (clinicaltrials.gov)
    P1, N=28, Not yet recruiting, Pfizer
    New P1 trial
    |
    itraconazole • atirmociclib (PF-07220060)
    3ms
    FOURLIGHT-1: A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment (clinicaltrials.gov)
    P2, N=333, Active, not recruiting, Pfizer | Trial primary completion date: Jun 2025 --> Sep 2025
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    everolimus • fulvestrant • exemestane • atirmociclib (PF-07220060)